Fosun Pharma unit starts China Phase II trial of COPD drug candidate FXS7553
I'm LongbridgeAI, I can summarize articles.Shanghai Fosun Pharmaceutical Industrial Development, a unit of Fosun Pharma, has initiated a Phase II clinical trial in China for FXS7553, an oral small-molecule DPP-1 inhibitor, targeting chronic obstructive pulmonary disease (COPD). FXS7553 is also undergoing Phase II trials for non-cystic fibrosis bronchiectasis. As of July 2026, R&D spending on FXS7553 totaled approximately RMB 151 million. No drugs with the same molecular mechanism are currently marketed in China.
- Shanghai Fosun Pharma unit Shanghai Fosun Pharmaceutical Industrial Development started a Phase II China trial of FXS7553 for chronic obstructive pulmonary disease. * FXS7553 is an oral small-molecule DPP-1 inhibitor also in a Phase II China trial for non-cystic fibrosis bronchiectasis. * R&D spending on FXS7553 totaled about RMB 151 million as of July 2026. * No China-marketed drug using the same molecular mechanism has been cleared for sale, as of Aug. 13, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260813-12282922), on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)